Progress of Clinical Research on Triple-Negative Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XU Jianli , WU Chengyi.

Department of Endocrine Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaCorresponding Author: WU Cheng-yi, E-mail： nfmwk1192@hospital-cqmu.com;

Corresponding author：

Keywords：

Breast neoplasm; Triple-negative; BRCA1; Clinical feature; Treatment

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

　Objective 　To summarize the progress of clinical research on triple-negative breast cancer (TNBC).
　Methods 　Domestic and international publications on the study of TNBC in recent years were collected and reviewed.
　Results 　The patients with TNBC were younger, and their prognosis was poorer. Besides operation, chemotherapy was the major therapeutic tool for them. Currently the targeted therapy for epidermal growth factor receptor and its signal conducting system was applied to clinical therapy gradually， and it might benefit the patients with TNBC.
　Conclusion 　The study on TNBC may bring a new way for therapy.

Citation： XU Jianli,WU Chengyi.. Progress of Clinical Research on Triple-Negative Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(3): 252-256. doi: Copy

1.	Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature， 2000; 406(6797):747.
2.	Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16):5367.
3.	Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer [J]. Mod Pathol, 2006; 19(5):617.
4.	Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors [J]. Mod Pathol, 2005; 18(10):1321.
5.	Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours [J]. Histopathology, 2006; 49(1):10.
6.	Sasa M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer [J]. J Surg Oncol, 2008; 97(1):30.
7.	Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [J]. Cancer, 2007; 109(1):25.
8.	Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies [J]. Breast, 2007; 16(1):104.
9.	Litwiniuk MM, Roznowski K, Filas V, et al. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers [J]. BMC Cancer, 2008; 8:100.
10.	Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer [J]. J Clin Oncol, 2008; 26(26):4282.
11.	Wysocki PJ, Korski K, Lamperska K, et al. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations [J]. Med Sci Monit, 2008;　14(7):SC7.
12.	Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast [J]. Histopathology, 2006;　49(1):22.
13.	Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [J]. Mod Pathol, 2006;　19(2):264.
14.	Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry [J]. Cancer, 2007; 109(9):1721.
15.	Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J]. Clin Cancer Res, 2007; 13(15 Pt 1):4429.
16.	Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004 [J]. Cancer, 2008; 112(4):737.
17.	Ihemelandu CU, Naab TJ, Mezghebe HM, et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women [J]. Am J Surg, 2008; 195(2):153.
18.	Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol, 2008; 26(8):1275.
19.	Wang X, Chao L, Ma G, et al. Increased expression of osteopontin in patients with triple-negative breast cancer [J]. Eur J Clin Invest, 2008; 38(6):438.
20.	Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage Ⅱ/Ⅲ breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer [J]. BMC Cancer, 2007; 7:203.
21.	Rouzier R, Pusztai L, Garbay JR, et al. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer [J]. Cancer, 2006; 107(7):1459.
22.	Gluz O, Nitz UA, Harbeck N, et al. West German Study Group. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial [J]. Ann Oncol, 2008; 19(5):861.
23.	Falo C, Moreno A, Varela M, et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy [J]. J Cancer Res Clin Oncol, 2007; 133(7):423.
24.	Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res, 2007; 13(8):2329.
25.	Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [J]. Breast Cancer Res Treat, 2008; 111(1):27.
26.	Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer [J]. Ann Oncol, 2008; 19(11):1847.
27.	Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel [J]. Cancer Chemother Pharmacol, 2008; 62(4):667.
28.	Tischkowitz M, Brunet JS, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer [J]. BMC Cancer, 2007; 7:134.
29.	Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis [J]. Breast Cancer Res, 2005; 7(6):R1028.
30.	Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level [J]. Nat Rev Mol Cell Biol, 2006; 7(7):505.
31.	Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors [J]. Nat Rev Cancer, 2005; 5(5):341.
32.	Modi S, D’Andrea G, Norton L, et al. A phase Ⅰ study of cetuximab/paclitaxel in patients with advanced-stage breast cancer [J]. Clin Breast Cancer, 2006;　7(3):270.
33.	Dennison SK, Jacobs SA, Wilson JW, et al. A phase Ⅱ clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer [J]. Invest New Drugs, 2007; 25(6):545.
34.	Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer [J]. Drugs, 2007; 67(12):1793.

1. Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature， 2000; 406(6797):747.
2. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16):5367.
3. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer [J]. Mod Pathol, 2006; 19(5):617.
4. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors [J]. Mod Pathol, 2005; 18(10):1321.
5. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours [J]. Histopathology, 2006; 49(1):10.
6. Sasa M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer [J]. J Surg Oncol, 2008; 97(1):30.
7. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [J]. Cancer, 2007; 109(1):25.
8. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies [J]. Breast, 2007; 16(1):104.
9. Litwiniuk MM, Roznowski K, Filas V, et al. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers [J]. BMC Cancer, 2008; 8:100.
10. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer [J]. J Clin Oncol, 2008; 26(26):4282.
11. Wysocki PJ, Korski K, Lamperska K, et al. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations [J]. Med Sci Monit, 2008;　14(7):SC7.
12. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast [J]. Histopathology, 2006;　49(1):22.
13. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [J]. Mod Pathol, 2006;　19(2):264.
14. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry [J]. Cancer, 2007; 109(9):1721.
15. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J]. Clin Cancer Res, 2007; 13(15 Pt 1):4429.
16. Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004 [J]. Cancer, 2008; 112(4):737.
17. Ihemelandu CU, Naab TJ, Mezghebe HM, et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women [J]. Am J Surg, 2008; 195(2):153.
18. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J]. J Clin Oncol, 2008; 26(8):1275.
19. Wang X, Chao L, Ma G, et al. Increased expression of osteopontin in patients with triple-negative breast cancer [J]. Eur J Clin Invest, 2008; 38(6):438.
20. Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage Ⅱ/Ⅲ breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer [J]. BMC Cancer, 2007; 7:203.
21. Rouzier R, Pusztai L, Garbay JR, et al. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer [J]. Cancer, 2006; 107(7):1459.
22. Gluz O, Nitz UA, Harbeck N, et al. West German Study Group. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial [J]. Ann Oncol, 2008; 19(5):861.
23. Falo C, Moreno A, Varela M, et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy [J]. J Cancer Res Clin Oncol, 2007; 133(7):423.
24. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes [J]. Clin Cancer Res, 2007; 13(8):2329.
25. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients [J]. Breast Cancer Res Treat, 2008; 111(1):27.
26. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer [J]. Ann Oncol, 2008; 19(11):1847.
27. Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel [J]. Cancer Chemother Pharmacol, 2008; 62(4):667.
28. Tischkowitz M, Brunet JS, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer [J]. BMC Cancer, 2007; 7:134.
29. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis [J]. Breast Cancer Res, 2005; 7(6):R1028.
30. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level [J]. Nat Rev Mol Cell Biol, 2006; 7(7):505.
31. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors [J]. Nat Rev Cancer, 2005; 5(5):341.
32. Modi S, D’Andrea G, Norton L, et al. A phase Ⅰ study of cetuximab/paclitaxel in patients with advanced-stage breast cancer [J]. Clin Breast Cancer, 2006;　7(3):270.
33. Dennison SK, Jacobs SA, Wilson JW, et al. A phase Ⅱ clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer [J]. Invest New Drugs, 2007; 25(6):545.
34. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer [J]. Drugs, 2007; 67(12):1793.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Progress of Clinical Research on Triple-Negative Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content